Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients.

Makhlough A, Shekarchian S, Moghadasali R, Einollahi B, Hosseini SE, Jaroughi N, Bolurieh T, Baharvand H, Aghdami N.

Stem Cell Res Ther. 2017 May 23;8(1):116. doi: 10.1186/s13287-017-0557-7.

2.

Ouabain promotes partial epithelial to mesenchymal transition (EMT) changes in human autosomal dominant polycystic kidney disease (ADPKD) cells.

Venugopal J, McDermott J, Sanchez G, Sharma M, Barbosa L, Reif GA, Wallace DP, Blanco G.

Exp Cell Res. 2017 Jun 15;355(2):142-152. doi: 10.1016/j.yexcr.2017.04.001. Epub 2017 Apr 3.

PMID:
28385574
3.

Identification and Expression Analysis of the Complete Family of Zebrafish pkd Genes.

England SJ, Campbell PC, Banerjee S, Swanson AJ, Lewis KE.

Front Cell Dev Biol. 2017 Feb 21;5:5. doi: 10.3389/fcell.2017.00005. eCollection 2017.

4.

Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014).

Fernando MR, Dent H, McDonald SP, Rangan GK.

Popul Health Metr. 2017 Feb 17;15(1):7. doi: 10.1186/s12963-017-0123-7.

5.

Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.

Lai S, Petramala L, Mastroluca D, Petraglia E, Di Gaeta A, Indino E, Panebianco V, Ciccariello M, Shahabadi HH, Galani A, Letizia C, D'Angelo AR.

Medicine (Baltimore). 2016 Jul;95(29):e4175. doi: 10.1097/MD.0000000000004175.

6.

The functions of TRPP2 in the vascular system.

Du J, Fu J, Xia XM, Shen B.

Acta Pharmacol Sin. 2016 Jan;37(1):13-8. doi: 10.1038/aps.2015.126. Review.

7.

Vascular complications in autosomal dominant polycystic kidney disease.

Perrone RD, Malek AM, Watnick T.

Nat Rev Nephrol. 2015 Oct;11(10):589-98. doi: 10.1038/nrneph.2015.128. Epub 2015 Aug 11. Review.

8.

Pheochromocytoma as a rare cause of arterial hypertension in a patient with autosomal dominant polycystic kidney disease: A diagnostic and therapeutic dilemma.

Hessheimer AJ, Vidal O, Valentini M, García-Valdecasas JC.

Int J Surg Case Rep. 2015;14:85-8. doi: 10.1016/j.ijscr.2015.07.015. Epub 2015 Jul 28.

9.

Closeout of the HALT-PKD trials.

Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC.

Contemp Clin Trials. 2015 Sep;44:48-55. doi: 10.1016/j.cct.2015.07.017. Epub 2015 Jul 29.

10.

Successful Endovascular Stent-Graft Repair for Complicated Type B Aortic Dissection Developed in a Patient with Polycystic Kidney Disease.

Jung CS, Park BW, Bang DW, Jang WH, Kim HS, Oh JH.

Vasc Specialist Int. 2015 Jun;31(2):58-61. doi: 10.5758/vsi.2015.31.2.58. Epub 2015 Jun 30.

11.

Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated.

Cabrera-López C, Bullich G, Martí T, Català V, Ballarín J, Bissler JJ, Harris PC, Ars E, Torra R.

BMC Med Genet. 2015 Jun 17;16:39. doi: 10.1186/s12881-015-0185-y.

12.

Cystinuria in a patient with polycystic kidney disease.

Love K, Yeo FE.

NDT Plus. 2009 Feb;2(1):30-3. doi: 10.1093/ndtplus/sfn166. Epub 2008 Nov 11.

13.

Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease.

Blanchette CM, Liang C, Lubeck DP, Newsome B, Rossetti S, Gu X, Gutierrez B, Lin ND.

Drugs Context. 2015 Apr 17;4:212275. doi: 10.7573/dic.212275. eCollection 2015.

14.

Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.

Piazzon N, Bernet F, Guihard L, Leonhard WN, Urfer S, Firsov D, Chehade H, Vogt B, Piergiovanni S, Peters DJ, Bonny O, Constam DB.

J Transl Med. 2015 Mar 30;13:103. doi: 10.1186/s12967-015-0463-7.

15.

End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases.

Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B.

Clinicoecon Outcomes Res. 2015 Jan 6;7:65-72. doi: 10.2147/CEOR.S76269. eCollection 2015.

16.

Identification of Biomarkers for PKD1 Using Urinary Exosomes.

Hogan MC, Bakeberg JL, Gainullin VG, Irazabal MV, Harmon AJ, Lieske JC, Charlesworth MC, Johnson KL, Madden BJ, Zenka RM, McCormick DJ, Sundsbak JL, Heyer CM, Torres VE, Harris PC, Ward CJ.

J Am Soc Nephrol. 2015 Jul;26(7):1661-70. doi: 10.1681/ASN.2014040354. Epub 2014 Dec 4.

17.

Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.

McGovern AP, Jones S, van Vlymen J, Saggar AK, Sandford R, de Lusignan S.

BMC Nephrol. 2014 Nov 20;15:182. doi: 10.1186/1471-2369-15-182.

18.

Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing.

Trujillano D, Bullich G, Ossowski S, Ballarín J, Torra R, Estivill X, Ars E.

Mol Genet Genomic Med. 2014 Sep;2(5):412-21. doi: 10.1002/mgg3.82. Epub 2014 May 23.

19.

ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.

Reule S, Sexton DJ, Solid CA, Chen SC, Collins AJ, Foley RN.

Am J Kidney Dis. 2014 Oct;64(4):592-9. doi: 10.1053/j.ajkd.2014.05.020. Epub 2014 Aug 16.

20.

The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia.

Mallett A, Patel C, Salisbury A, Wang Z, Healy H, Hoy W.

Orphanet J Rare Dis. 2014 Jun 30;9:98. doi: 10.1186/1750-1172-9-98.

Supplemental Content

Support Center